Evidence of lung function for stratification of cardiovascular disease risk

Korean Circulation Journal

Volumn 41, Issue 4, 2011, Pages 171-174

  Lee, Hwa Mu ^a   Truong, Steven T ^a   Wong, Nathan D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Respiratory function test

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRAMINGHAM RISK SCORE; HEART INFARCTION; HUMAN; IMMUNOMODULATION; INFLAMMATION; ISCHEMIC HEART DISEASE; LUNG FUNCTION; MORTALITY; PEAK EXPIRATORY FLOW; PRACTICE GUIDELINE; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SUDDEN DEATH; SYMPTOM;

EID: 79957852766     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2011.41.4.171     Document Type: Review

References (41)

1. Gluckman TJ, Baranowski B, Ashen MD, et al. A practical and evidence-based approach to cardiovascular disease risk reduction. Arch Intern Med 2004;164:1490-500. (Pubitemid 38970467)
2. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53. (Pubitemid 351640675)
3. Thompson JB, Rivera JJ, Blumenthal RS, Danyi R Primary prevention for patients with intermediate Framingham risk scores. Curr Cardiol Rep 2006;8:261-6. (Pubitemid 44043980)
4. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 1990;65:168-72.
5. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9. (Pubitemid 36158034)
6. th Bethesda conference task force #4: how do we select patients for atherosclerosis imaging? J Am Coll Cardiol 2003;41:1898-906.
7. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA writing committee to update the 2000 expert consensus document on electron beam computed tomography) developed in collaboration with the society of atherosclerosis imaging and prevention and the society of cardiovascular computed tomography. J Am Coll Cardiol 2007;49:378-402.
8. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R Sr, O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008;1:92-7.
9. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: assessment of cardiovascular risk in asymptomatic adults. J Am Coll Cardiol 2010;56:50-103, doi: 10.1016/j.jacc.2010.09.001.
10. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74. (Pubitemid 36019640)
11. Nilsson J. CRP: marker or marker of cardiovascular disease? Arterioscler Thromb Vasc Biol 2005;25:1527-8. (Pubitemid 41098915)
12. Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 2006;113:2128-34; discussion 2151.
13. Kannel WB, Hubert H, Lew EA. Vital capacity as a predictor of cardiovascular disease: the Framingham Study. Am Heart J 1983;105:311-5. (Pubitemid 13188283)
14. Marcus EB, Curb JD, MacLean CJ, Reed DM, Yano K. Pulmonary function as a predictor of coronary heart disease. Am J Epidemiol 1989;129:97-104. (Pubitemid 19030702)
15. Enström G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002;106:2555-60. (Pubitemid 35340691)
16. Schroeder EB, Welch VL, Couper D, et al. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2003;158:1171-81. (Pubitemid 37548787)
17. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952-9.
18. Higgins MW, Keller JB. Predictors of mortality in the adult population of Tecumseh. Arch Environ Health 1970;21:418-24.
19. Beaty TH, Newill CA, Cohen BH, Tockman MS, Bryant SH, Spurgeon HA. Effects of pulmonary function on mortality. J Chronic Dis 1985;38:703-10. (Pubitemid 16237420)
20. Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington county, Maryland. Am Rev Respir Dis 1989;140:S56-63.
21. Hole DJ, Watt GC, Darvey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung function and mortality risks in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711-5.
22. Schünemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest 2000;118:656-64.
23. Curb JD, Marcus EB, Reed DM, MacLean C, Yano K. Smoking, pulmonary function and mortality. Ann Epidemiol 1990;1:25-32.
24. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Spirometric findings and mortality in never smokers. J Clin Epidemiol 1990;43:867-73.
25. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-9. (Pubitemid 36378490)
26. Lee HM, Le H, Lee BT, Lopez VA, Wong ND. Forced vital capacity paired with Framingham risk score for prediction of all-cause mortality. Eur Respir J 2010;36:1022-6.
27. Jiang R, Burke GL, Enright PL, et al. Inflammatory markers and longitudinal lung function decline in the elderly. Am J Epidemiol 2008;168:602-10.
28. Thyagarajan B, Jacobs DR, Apostol GG, Smith LJ, Lewis CE, Williams OD. Plasma fibrinogen and lung function: the CARDIA Study, Int J Epidemiol 2006;35:1001-8. (Pubitemid 44540754)
29. Hancox RJ, Poulton R, Greene JM, et al. Systemic inflammation and lung function in young adults. Thorax 2007;62:1064-8. (Pubitemid 350206198)
30. Shaaban R, Kony S, Driss F, et al. Change in C-reactive protein levels and FEV1 decline: A longitudinal population-based study. Respir Med 2006;100:2112-20. (Pubitemid 44752671)
31. Fogarty AW, Jones S, Britton JR, Lewis SA, McKeever TM. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007;62:515-20. (Pubitemid 46910130)
32. Lee HM, Le TV, Lopez VA, Wong ND. Association of C-reactive protein with reduced forced vital capacity in a nonsmoking U. S. population with metabolic syndrome and diabetes. Diabetes Care 2008,31:2000-2.
33. Gan WQ, Man SF, Senthilsevan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80. (Pubitemid 38901515)
34. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the third national health and nutrition examination. Am J Med 2003;114:758-62. (Pubitemid 36776358)
35. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers inpatients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006;47:2554-60. (Pubitemid 43866389)
36. Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279-83. (Pubitemid 46237383)
37. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007;131:1006-12. (Pubitemid 46608700)
38. Keddissi JI, Younis WG, Chbeir EA, Daher NN, Demaika TA, Kinasewitz GT. The use of statins and lung function in current and former smokers. Chest 2007;132:1764-71.
39. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax 2006;61:472-7. (Pubitemid 43901515)
40. Mannino DM, Reichert MM, Davis KJ. Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med 2006;173:985-90.
41. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systemic review. Chest 2009;136:734-43.